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Amyloid Precursor Protein Cleavage-Dependent and
-Independent Axonal Degeneration Programs Share a
Common Nicotinamide Mononucleotide Adenylyltransferase
1-Sensitive Pathway
Bhupinder P. S. Vohra,1,4* Yo Sasaki,1* Bradley R. Miller,2 Jufang Chang,1 Aaron DiAntonio,2,3 and Jeffrey Milbrandt1,3
Departments of 1Genetics and 2Developmental Biology, and 3HOPE Center for Neurological Disorders, Washington University School of Medicine, St. Louis,
Missouri 63110, and 4Biology Department, University of Central Arkansas, Conway, Arkansas 72034

Axonal degeneration is a hallmark of many debilitating neurological disorders and is thought to be regulated by mechanisms distinct
from those governing cell body death. Recently, caspase 6 activation via amyloid precursor protein (APP) cleavage and activation of DR6
was discovered to induce axon degeneration after NGF withdrawal. We tested whether this pathway is involved in axonal degeneration
caused by withdrawal of other trophic support, axotomy or vincristine exposure. Neurturin deprivation, like NGF withdrawal activated
this APP/DR6/caspase 6 pathway and resulted in axonal degeneration, however, APP cleavage and caspase 6 activation were not involved
in axonal degeneration induced by mechanical or toxic insults. However, loss of surface APP (sAPP) and caspase 6 activation were
observed during axonal degeneration induced by dynactin 1(Dctn1) dysfunction, which disrupts axonal transport. Mutations in Dctn1
are associated with motor neuron disease and frontal temporal dementia, thus suggesting that the APP/caspase 6 pathway could be
important in specific types of disease-associated axonal degeneration. The NGF deprivation paradigm, with its defined molecular pathway, was used to examine the context of Nmnat-mediated axonal protection. We found that although Nmnat blocks axonal degeneration
after trophic factor withdrawal, it did not prevent loss of axon sAPP or caspase 6 activation within the axon, suggesting it acts downstream
of caspase 6. These results indicate that diverse insults induce axonal degeneration via multiple pathways and that these degeneration
signals converge on a common, Nmnat-sensitive program that is uniquely involved in axonal, but not cell body, degeneration.

Introduction
Why is axonal degeneration a common element of a diverse set of
neurological disorders? A favorite hypothesis is that a wide range
of neuronal insults triggers a general axonal self-destruction program. In support of this hypothesis, overexpression of Wld s, or
its component Nmnat, blocks degeneration in response to many
distinct stimuli (Mack et al., 2001; Ferri et al., 2003; Araki et al.,
2004; Sasaki et al., 2006, 2009a,b; Yahata et al., 2009). The intrinsic pathways that drive degeneration are poorly understood,
however calcium influx, regulated protein degradation, and JNK

Received June 8, 2010; revised July 15, 2010; accepted July 26, 2010.
This work was supported by National Institutes of Health (NIH) Neuroscience Blueprint Center Core Grant P30
NS057105 to Washington University; the HOPE Center for Neurological Disorders, Washington University ADRC NIA
P50 AG05681-25 (A.D.) and NIH Grants NS040745 (J.M.), AG13730 (J.M.), and NS065053 (A.D. and J.M.); Muscular
Dystrophy Association Grants 10040 (J.M.); and Craig H. Neilsen Foundation Grant 124030 (J.M.). We thank Kelli
Simburger, Amy Strickland, Amber Neilson, and Tim Fahrner for experimental assistance, and members of the
Milbrandt laboratory for their comments on this manuscript and helpful discussions.
The authors and Washington University may derive benefit from a licensing agreement with Sirtris Pharmaceuticals, which did not provide any support for this work.
*B.P.S.V. and Y.S. contributed equally to this work.
Correspondence should be addressed to Jeffrey Milbrandt, Washington University School of Medicine, 660 South
Euclid Avenue, Box 8118, St. Louis, MO 63110. E-mail: jmilbrandt@wustl.edu.
DOI:10.1523/JNEUROSCI.2939-10.2010
Copyright © 2010 the authors 0270-6474/10/3013729-10$15.00/0

activation by DLK have all been implicated (Coleman, 2005; Luo
and O’Leary, 2005; Miller et al., 2009).
A general molecular pathway leading from the initial insult to
the effectors of axonal breakdown has remained elusive. Although axonal destruction shares morphological features with
apoptosis, most studies indicate that it is a caspase-independent
process as manipulation of the mitochondrial apoptotic machinery or caspase inhibitors fail to block axonal degeneration (Sagot
et al., 1995; Finn et al., 2000; Watts et al., 2003; Whitmore et al.,
2003). Recently, however a candidate pathway for axonal degeneration following NGF withdrawal that involves activation of
caspase 6 was identified (Nikolaev et al., 2009). In this paradigm,
removal of nerve growth factor (NGF) initiates a cascade of
events whereby axonal APP is cleaved and the shed N-terminal
APP fragment activates the tumor necrosis factor (TNF) receptor
DR6. The activation of DR6 leads to caspase 6 activation and
eventual axonal destruction.
Defects in axonal transport and insufficient trophic support
are thought to be involved in many neurological disorders (De
Vos et al., 2008). Dctn1 is a component of the dynactin complex
that interacts with dynein to facilitate retrograde transport of
cargoes from the axon terminal to the neuronal cell body. Missense mutations in DCTN1, which encodes dynactin 1, are linked
to slowly progressing motor neuron diseases, ALS, ALS with
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FTD, and Perry syndrome (Puls et al.,
2003, 2005; Münch et al., 2004, 2005;
Wider and Wszolek, 2008; Farrer et al.,
2009; Vilariño-Güell et al., 2009). Patients
with these mutations also manifest mild
sensory neuropathy (Puls et al., 2005).
Mutation of DCTN1 is thought to cause
neuronal dysfunction via disruption of
retrograde axonal transport that results in
decreased availability of trophic factors in
the cell body. Because of the potential involvement in trophic factor deprivation,
we hypothesized that the APP/DR6/
caspase 6 pathway could play a role in
neurological disorders caused by defective
axonal transport. Furthermore, this pathway could also be involved in axonal degeneration due to mechanical injury, as
blocking APP cleavage reduces axonal degeneration, neuronal loss and cognitive
deficits resulting from traumatic brain injury (Loane et al., 2009). The identification of this APP-dependent pathway is an
important advance in our understanding
of the mechanism of axonal degeneration,
however it remains unclear whether APP
processing is a common initiating step in
axonal degeneration or instead in one of
multiple stimulus-dependent axonal degeneration programs (for review, see Kim
and Tsai, 2009; Wiedemann, 2009).

Materials and Methods

Figure 1. Distinct pathways of axonal degeneration activated by trophic factor deprivation, axotomy and vincristine intoxication. A, Dorsal root ganglia (DRG) were cultured for 5 d and axonal degeneration was induced by NGF withdrawal [NGF (-)],
axotomy or vincristine. Treatment with the BACE inhibitor (BACEi; OM99-2), which inhibits APP cleavage, or anti-N-terminal
APP-blocking antibody (ab N-APP) blocked axonal degeneration caused by NGF withdrawal, but not degeneration caused by
axotomy or vincristine. Similarly, caspase 6 inhibitor (Caspase 6i; zVEID-FMK) and overexpression of Bcl-xl delayed axonal degeneration caused by NGF deprivation only. In contrast, expression of cytNmnat1 prevented axonal degeneration in all paradigms
tested. B–D, Image analysis software was used to provide a quantitative analysis of axonal degeneration (i.e., degeneration index)
after NGF deprivation (B), axotomy (C), and vincristine administration (D). These analyses highlight the fact that BACE inhibitor,
N-APP-blocking antibody, caspase 6 inhibitor and Bcl-xl only block axonal degeneration stimulated by NGF withdrawal, whereas
cytNmnat1 protected axons after all insults tested. Degeneration indices before treatment insults are indicated as 0 h. Significantly
different (*p ⬍ 0.001, Student’s t test) from neurons at time 0 (0 h NGF withdrawal).

Reagents. The following primary antibodies
were used: Anti-amyloid precursor protein (1:
100; MAB348, Millipore), Active Caspase-6
Polyclonal Antibody (1:100, BioVision), antiN-APP polyclonal antibody (20 g/ml, Fisher
Scientific), Neurofilament mouse monoclonal
(1:1000, Sigma-Aldrich). The secondary antibodies used were Alexa Fluor 488- and 594conjugated anti-mouse and anti-rabbit antibodies
(1:500; Invitrogen). BACE inhibitor (10 M;
OM99-2) and cell-permeable caspase 6 inhibitor (VEID-CHO) were purchased from Calbiochem. The Apo Logix carboxyfluorescein caspase 6 detection kit was purchased from Cell
Technology Inc. All other reagents were from Sigma-Aldrich unless otherwise noted.
Culture of SCG and DRGs. Tissue culture plates were coated with
poly-D-lysine and laminin (Invitrogen) and neurons were cultured as
previously described (Sasaki et al., 2009a). Briefly, DRGs were collected from CD1 mouse (Charles River) embryos at embryonic day
12.5, whereas SCGs were collected from P0 Pups. DRGs were treated
with 0.05% trypsin and 0.02% EDTA at 37°C for 15 min. SCGs were
dissociated with collagenase (1 mg/ml) at 37°C for 30 min which was
followed by trypsinization for 15 min at 37°C. After dissociation,
DRGs and SCGs were triturated by passing repeatedly through a 1 ml
pipette tip and resuspended in 500 l of Neurobasal medium (Invitrogen) containing 0.2% B27 (Invitrogen) and 50 ng/ml NGF (2.5S;
Harlan Bioproducts). After brief centrifugation (2000 ⫻ g), the cell
pellet was resuspended in 50 l of complete medium and neurons
were plated using drop culture method by placing (2 l) of cell suspension slightly below the center of each 24 well and incubated at
37°C with 5% CO2 for 1 h. After cell attachment, 500 l of complete
medium containing 1 M 5-fluoro-2-deoxyuridine, and 1 M uridine
was added to each well.

Lentivirus-mediated gene knockdown. Oligonucleotides were designed
to target proteins using parameters set by Genescript on its siRNA design
website (Genescript) (Wang and Mu, 2004). Fifty-nine base pair oligonucleotides were engineered containing both forward and reverse sequences for the 19 bp siRNA target sequences linked together with a
hairpin loop, and ligated into AgeI-BamHI cut pFUHIV downstream of
the U6 promoter (Chen et al., 2006). The lentiviral-expressing siRNAs
were produced and the efficiency of knockdown was ascertained by measuring the Dctn1 mRNA levels. The target sequences used were siRNA #1
GCAGTGTGGACGTGTATAA, siRNA #2 GAAGATCCGAAGGCGGATG and siRNA #3 CCAGAGACTTTTGATTTCA.
Construction of lentiviral expression plasmids. mCherry was obtained
from Dr. Roger Tsien (University of California, San Diego, La Jolla, CA)
(Sharner et al., 2004). The cytNmnat1-mCherry fusion gene and Bcl-xl
cDNA (kindly provided by S. J. Weintraub, Washington University, St. Louis,
MO) were cloned into a lentiviral expression plasmid (Lois et al., 2004).
Trophic factor deprivation. For NGF withdrawal experiments, SCG
neurons were grown in NGF-containing medium (50 ng/ml) cultured
for 5 d in vitro (DIV5). The NGF-containing medium was removed
and neurons were washed with NGF-depleted medium twice. Neurons were then grown in NGF-depleted neurobasal/B27 medium containing goat anti-NGF antibody (1:1000). For Neurturin deprivation
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Figure 2. Loss of axonal sAPP is not involved in axonal degeneration induced by mechanical or toxin damage. A–C, Immunofluorescent microscopic analysis using an antibody to the APP N
terminus to examine the “patchy” loss of surface APP (sAPP) on axons of neurons deprived of NGF (A), following axotomy (B), or treated with vincristine (C). Note the loss of sAPP following NGF
withdrawal but not after mechanical or toxic insults, and that the loss of sAPP after NGF withdrawal persists despite the expression of cytNmnat1 or Bcl-xl. Quantification of the percentage of axons
with decreased sAPP is displayed for each condition (see Materials and Methods). D, Conditioned medium was subjected to Western blot analysis for cleaved N-terminal APP fragment using
anti-N-APP antibody. The presence of shed N-terminal APP fragments was detected after NGF deprivation even under conditions where the axons were protected due to overexpression of Bcl-xl or
cytNmnat1. Significantly different (*p ⬍ 0.001, Student’s t test) from neurons grown in the presence of NGF.
experiments, SCG neurons were established and grown for 2 d in
NGF-containing medium. The neurons were washed with Neurobasal
medium containing 0.2% B27 to remove NGF and then cultured in
Neurobasal medium containing 0.2% B27 and Neurturin (40 ng/ml).
After 3 d, the neurons were washed twice with neurobasal containing
0.2% B27 without Neurturin and then cultured in Neurturin-free
medium.
Inhibitor and APP-blocking antibody treatment. In all the experiments,
inhibitors (caspase 6 inhibitor; 25 M, BACE inhibitor; 10 M) and APPblocking antibody (anti-APP; 20 g/ml, Fisher Scientific) were added to
the medium at the time of NGF withdrawal and axotomy or vincristine
treatment.
Axotomy and vincristine treatment. Axons were severed by a microscalpel (Fine Science Tools) after DIV5. Vincristine was added after DIV5
at a concentration of 0.04 M in NGF-supplemented medium.
Lentiviral infection of DRG neurons. For infection of DRG neurons,
lentivirus (10 5–10 6 infectious units) was added at DIV1 and 4 d later (to
allow for adequate transgene expression) experiments were performed.

Viral infection and transgene expression were examined via fluorescent
microscopy of the EGFP or mCherry reporter.
Dctn1 siRNA studies. DRG neurons (DIV1) were infected with
lentivirus-expressing Dctn1 or Luciferase siRNAs. To test the effects of
Bcl-xl and cytNmnat1 overexpression, cells were simultaneously infected
with lentiviruses expressing Dctn1 siRNA, along with viruses expressing
Bcl-xl or cytNmnat1. After infection, cultures were maintained for an
additional 7 d in the presence of 50 ng/ml NGF. To monitor neuronal cell
death, ethidium homodimer (100 nM final) was added, cells were fixed
after 30 min, and fluorescent (dead) DRG neurons were counted. Axonal
degeneration was assessed as described below.
NGF internalization assay. Lyophilized NGF was fluorescently labeled
using a Cy3 labeling kit as per manufacturer’s instructions (GE Healthcare Biosciences). DRG neurons were plated in the inner chamber of
compartmentalized chambers, maintained for 14 d, and then infected
with lentiviruses expressing either Dctn1 or Luciferase siRNA. Seven days
postinfection NGF was removed from both the inner (cell body) and the
outer (axonal) chambers and the neurons were incubated overnight in
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Figure 3. Nmnat1 protects axons in the presence of activated caspase 6 and axonal degeneration induced by axotomy and vincristine does not involve caspase 6 activation. Immunofluorescence
detection of cleaved caspase 6 in SCG axons (top, microtubule staining; bottom, cleaved caspase 6 staining) reveals that caspase 6 is activated within 20 h after NGF deprivation. The activation of
caspase 6 is blocked by expression of Bcl-xl but not by the expression of cytNmnat1, despite the fact that cytNmnat1 effectively prevents axonal fragmentation after NGF withdrawal. Immunofluorescence analysis of cleaved caspase 6 in SCG neurons revealed that caspase 6 is not activated after axotomy or vincristine treatment.
medium lacking NGF. Cy3-NGF (100 ng/ml final) was added to the
axonal compartment and incubated at 37°C for 4 h. The percentage of
Cy3-positive neurons (indicating internalized NGF) was determined using fluorescence microscopy.
Immunohistochemistry. After fixation, cells were washed with PBS and
blocked with 4% normal donkey serum in TBST (Tris-buffered saline
plus 0.1% Triton X-100) (1 h, 37°C). Cells were incubated in primary
antibody (4°C overnight) and antibody binding was visualized with Alexa Fluor 488- or 594-conjugated anti-mouse and anti-rabbit secondary
antibodies (25°C, 1 h). To visualize APP on the axonal surface, cells were
incubated with MAB348 (1:100) without permeabilization. Cells were
incubated in primary antibody (4°C overnight) and antibody binding
was visualized with Alexa Fluor 594-conjugated anti-mouse secondary
antibody (25°C, 1 h). For quantification of sAPP loss, axons showing at
least four patches of decreased staining (i.e., areas of sAPP loss) were
counted from 4 random fields for each condition. Each experiment was
repeated three times and the percentage of axons bearing ⬎4 patches of
APP loss was determined.
Quantification of axonal degeneration. Axonal degeneration was quantified as described previously (Sasaki et al., 2009a). Briefly, after axonal
severing, phase contrast images were taken using an inverted microscope
with a 20⫻ objective (Eclipse TE 300; Nikon). MetaMorph software
(Molecular Devices) was used to image 3– 4 random fields of distal axons
from each well with 40 ms exposure time by using CCD camera (Cool
SNAP ES; Nikon). After brightness and background intensity adjustment
by the auto-level function in Adobe Photoshop, images were analyzed by
NIH ImageJ. The total axonal area was determined by the total number of
detected pixels after binarization of the image. Nondegenerated axons
showed continuous tracts, while degenerating axons were fragmented,
beaded and showed up as aggregates. Degenerated axons were detected
using the particle analyzer of ImageJ as small particles, while healthy
axonal areas were represented as large continuous areas. The degeneration index is the ratio of fragmented axon area to total axon area. Sixteen
fields were evaluated for each condition and each experiment was repeated three times.

Results
N-terminal APP fragmentation is not a universal initiator of
axon degeneration
To test the generality of the APP/caspase 6 pathway for axon
degeneration, we used three distinct triggers of axonal degeneration in dorsal root ganglion (DRG) and superior cervical ganglion (SCG) neurons: NGF withdrawal, axotomy, and treatment
with the chemotherapeutic agent vincristine. If cleavage of APP is
the initial trigger for axonal degeneration, then blocking APP

cleavage with a BACE inhibitor or using anti-APP antibodies to
block its interaction with DR6 should block axonal degeneration
initiated by each of these insults. We treated DIV5 neurons with
the BACE inhibitor OM99-2 (10 M) or anti-N-terminal amyloid
precursor protein (N-APP) antibody (20 g/ml) at the time of
axonal injury. Axonal degeneration was monitored over 24 h
using phase-contrast microscopy and a degeneration index
(D. I.) was calculated (see Materials and Methods). Axonal degeneration increases dramatically after NGF deprivation (Fig. 1B;
supplemental Fig. S1, available at www.jneurosci.org as supplemental material). Consistent with previous findings, inhibiting
APP cleavage with a BACE inhibitor or a function-blocking antibody against the shed N-APP fragment blocked axonal degeneration triggered by NGF withdrawal (Fig. 1 A, B; supplemental
Fig. S1, available at www.jneurosci.org as supplemental material)
(Nikolaev et al., 2009). In contrast, neither the BACE inhibitor
nor the N-APP function-blocking antibody protected axons following axotomy or vincristine treatment (Fig. 1 A, C,D; supplemental Fig. S1, available at www.jneurosci.org as supplemental
material). Hence, APP shedding is necessary for axonal degeneration following trophic factor withdrawal but not for degeneration induced by mechanical or chemical insults.
Apoptotic pathways are not involved in axonal degeneration
caused by traumatic or toxin damage
While APP may be unnecessary for axonal degeneration following mechanical and neurotoxic insults, apoptotic pathways involving activation of caspase 6 may still be a common
downstream effector of diverse stimulus-dependent degeneration pathways. We used two methods to test the role of caspase 6
in axonal degeneration. First, we used Bcl-xl overexpression to
block activation of the mitochondrial apoptotic signaling pathway because it is downstream of N-APP-stimulated activation of
the DR6 receptor. Second, we evaluated the pharmacological inhibition of caspase 6. We also tested the effects of overexpression
of cytNmnat1, a cytosolic mutant of Nmnat1 (nicotinamide
mononucleotide adenylyltransferase 1) that provides robust axonal protection after axotomy (Sasaki et al., 2006). We found that
axonal degeneration following NGF withdrawal is blocked by
Bcl-xl, cytNmnat1 or caspase 6 inhibitors (Fig. 1 A, B; supplemental Fig. S1, available at www.jneurosci.org as supplemental mate-
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Figure 5. Neurturin deprivation results in loss of surface N-terminal APP and caspase 6
activation. A, Immunofluorescent microscopic analysis using an antibody to the APP N terminus
demonstrated the patchy loss of surface APP (sAPP) on axons of SCG neurons deprived of Neurturin. B, Active caspase 6 was detected in SCG axons via visualization with carboxyfluorescein
within 20 h after Neurturin withdrawal. C, Quantitative analysis of axonal degeneration in SCG
neurons deprived of Neurturin. Note that treatment with caspase 6 inhibitor (VEID-CHO) or
expression of Bcl-xl or cytNmnat1 protects against axonal degeneration induced by Neurturin
withdrawal. *Significantly different (p ⬍ 0.001, Student’s t test) from neurons grown in the
presence of Neurturin.

Figure 4. Bcl-xl inhibits both axonal and somal degeneration after NGF deprivation whereas
cytNmnat1 specifically inhibits axon degeneration. A, Phase contrast microscopy of DRG soma
cultured in the presence of NGF or 72 h after NGF deprivation. In the absence of NGF, extensive
cell soma degeneration was observed in control (⫺NGF) and cytNmnat1-expressing neurons
(⫺NGF/cytNmnat1). In contrast, Bcl-xl-expressing neuronal soma (⫺NGF/Bcl-xl) remained
refractile (alive) but were smaller than neurons grown in NGF. B, Quantitative analysis of refractile soma after NGF deprivation showed that most soma (⬎90%) degenerated 72 h after NGF
withdrawal in control, cytNmnat1-expressing, and caspase 6 inhibitor (caspase 6i)-treated DRG
neurons. The majority (68%) of Bcl-xl-expressing neuronal soma remained intact at 72 h after
NGF deprivation. Significantly different (*p ⬍ 0.001, Student’s t test) from control neurons
after NGF withdrawal. C, Quantification of activated caspase 3-positive neurons demonstrated
that neither caspase 6 inhibitors nor cytNmnat1 expression blocked caspase 3 activation in the
cell soma; however Bcl-xl expression completely blocked caspase 3 activation after NGF deprivation. Significantly different (*p ⬍ 0.001, Student’s t test) from neurons supplemented with
NGF. A total of 1100 neurons from each condition were counted and experiments were repeated
3 times.

rial), although the protection afforded by caspase 6 inhibition
was for a shorter time even with repeated daily additions of the
inhibitor (supplemental Fig. S2, available at www.jneurosci.org
as supplemental material, data not shown). In contrast to the
protection by cytNmnat1, axonal destruction initiated by axotomy or vincristine intoxication was not affected by caspase 6

inhibition or Bcl-xl overexpression (Fig. 1 A, C,D). These experiments demonstrate that loss of axonal sAPP, stimulation of apoptotic signaling, and caspase 6 activation are not involved in
axonal degeneration caused by mechanical or toxic insults and
imply that multiple pathways are involved in triggering axonal
degeneration.
While the APP/caspase pathway is selectively involved following trophic factor withdrawal, there are also likely to be shared
components in the pathways leading to axonal degeneration. For
example, Wld s and its functional component Nmnat effectively
block axonal degeneration caused by both mechanical and
chemical injuries and Wld s preserves NGF-deprived axons
(Deckwerth and Johnson, 1994; Mack et al., 2001; Araki et al.,
2004; Sasaki et al., 2006, 2009a,b), suggesting these injuries activate a common downstream axonal execution pathway. To test
this hypothesis we overexpressed a cytoplasmically targeted variant of Nmnat, cytNmnat1, that provides robust axonal protection (Sasaki et al., 2009b), in SCG neurons. In the presence of
cytNmnat1, axons are robustly protected from degeneration after
NGF deprivation, axotomy and vincristine treatment (Fig. 1 A–
C). As previously reported for wlds SCG neurons (Deckwerth and
Johnson, 1994), cytNmnat1 preserved both axonal integrity and
metabolic activity after NGF deprivation (supplemental Fig. S3,
available at www.jneurosci.org as supplemental material). These
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findings suggest that Nmnat-mediated
axonal protection occurs via the inhibition of a common axon degeneration
pathway.
cytNmnat1 does not block loss of
axonal sAPP or caspase 6 activation
after NGF withdrawal
Axonal degeneration after NGF deprivation
requires APP cleavage, N-APP fragment induced downstream signaling through the
DR6 receptor, and subsequent caspase 6 activation (Nikolaev et al., 2009). We therefore investigated whether N-APP shedding
occurs in response to other axonal degeneration insults by examining the surface loss of
APP on axons after axotomy and vincristine
treatment. As previously reported (Nikolaev
et al., 2009), NGF depletion induces the
loss of axonal surface immunoreactivity
for N-APP in patches (Fig. 2 A); however,
surface APP was not lost when axonal degeneration was induced by axotomy or
vincristine (Fig. 2 B, C). These results are
consistent with the lack of axonal protection by N-APP-blocking antibodies or
BACE inhibitors after mechanical or
Figure 6. Apoptotic pathways play important roles in axonal degeneration and cell death caused by Dctn1 knock down. A,
chemical injury (Fig. 1).
Phase contrast microscopy showing axonal degeneration 7 d after DRG neurons were infected with lentiviruses expressing LucifCaspase 6 activation is downstream of erase (Luc) or Dctn1 siRNA. Extensive axonal degeneration occurred after Dctn1 knockdown that was blocked by Bcl-xl expression,
N-APP generation (Nikolaev et al., 2009) caspase 6 inhibitor (caspase 6i) treatment, or cytNmnat1 expression. Axons of Luciferase siRNA-expressing neurons remained
and caspase 6 inhibition effectively blocks intact. B, Ethidium homodimer staining overlying phase contrast images of DRG neurons show extensive cell death in Dctn1
axonal degeneration after NGF with- knockdown neurons compared with those expressing Luciferase siRNA. Bcl-xl expression blocked cell death after Dctn1 knockdrawal. While caspase 6 inhibitors are down; however cytNmnat1 expression or caspase 6 inhibition failed to block neuronal death. C, Quantitative analysis of axonal
ineffective in preserving axons after me- degeneration (i.e., degeneration index) displayed in A demonstrated the protection afforded by Bcl-xl, caspase 6 inhibitor and
chanical or chemical injury, caspase 6 cytNmnat1. D, Quantification of ethidium homodimer-positive neurons showed that only Bcl-xl expression blocks neuronal cell
activation could be one of several inde- death caused by Dctn1 knockdown. The number of dead DRG neurons in each condition was scored and the percentage of dead
pendent mechanisms that drive axonal neurons is displayed. Significantly different (*p ⬍ 0.001, Student’s t test) from neurons expressing Luciferase siRNA.
degeneration induced by these insults. We
tective effects at a step that lies downstream (or parallel) to the
stained for activated caspase 6 after injury, and while we observed
loss of axonal sAPP and caspase 6 activation invoked by
a punctate staining pattern of activated caspase 6 in NGFNGF-deprivation.
deprived axons, we did not detect caspase 6 activation after axotomy or vincristine treatment (Fig. 3). Together, these results
lead us to conclude that loss of surface APP and caspase 6
Nmnat-mediated protection is restricted to axons
activation play essential roles in axonal demise induced by
Along with axonal degeneration, NGF withdrawal causes extenNGF withdrawal but that it is not involved in mechanical or
sive cell death. Interestingly, neurons from transgenic mice overtoxin-mediated axonal damage.
expressing Bcl-2 are protected from both axon and cell soma loss
The preservation of NGF-deprived axons by cytNmnat1 proafter NGF deprivation (Greenlund et al., 1995). Since both
vided an opportunity to investigate where Nmnat functions to
Nmnat1 and Bcl-xl protect axons from degeneration after troprotect axons doomed by activation of the APP/caspase 6 pathphic factor withdrawal, we investigated whether cytNmnat1 and
way. We first determined whether surface APP loss in SCG neuBcl-xl can also protect against NGF-deprived neuronal death.
rons expressing either cytNmnat1 or Bcl-xl occurred after NGF
Cell death was monitored by phase-contrast microscopy (Fig. 4)
withdrawal. Even though both molecules provided robust axonal
and ethidium homodimer uptake (supplemental Fig. S4, availprotection, neither protein blocked axonal sAPP loss as deterable at www.jneurosci.org as supplemental material). The permined by immunostaining (Fig. 2 A) or Western blot analysis of
centage of dead neurons increased until essentially all soma were
the conditioned media (Fig. 2 D), indicating that they both funcdegenerated (neuronal death) by 72 h after NGF-deprivation.
tion downstream of N-APP generation. Next, we examined the
Neurons expressing Bcl-xl showed minimal somal or axonal deeffects of cytNmnat1 and Bcl-xl overexpression on caspase 6 acgeneration; however, cell size was remarkably smaller than those
tivation in NGF-deprived axons. We observed robust axonal
maintained with NGF (Fig. 4 A; supplemental Fig. S5, available at
caspase 6 activation in control neurons, but not in those expresswww.jneurosci.org as supplemental material). In contrast, neuing Bcl-xl, indicating that the apoptotic cascade was blocked as
rons expressing cytNmnat1 had somal degeneration similar to
expected (Fig. 3). Surprisingly, cytNmnat1 did not block activacontrol neurons despite robust axonal protection. Further investion of caspase 6 despite the robust protection of these axons (Fig.
tigation revealed that soma degeneration followed a similar time
3). These results demonstrate that Nmnat exerts its axonal procourse in control and cytNmnat1-expressing neurons with 47 ⫾
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a more general phenomenon linked to loss of trophic support, we
examined the responses of SCG neurons to Neurturin deprivation. We chose to examine Neurturin because it also supports
SCG neuron growth and survival (Kotzbauer et al., 1996) as it
signals through a different receptor, namely a receptor complex
containing the Ret tyrosine kinase receptor (Baloh et al., 2000).
SCG neuronal cultures were established in NGF and then
switched to Neurturin. After growing for 3 d in Neurturin, Neurturin was withdrawn and neuronal death and axonal degeneration were examined. We found that Neurturin withdrawal caused
loss of surface APP (Fig. 5A) (patchy APP staining was observed
in only 6 ⫾ 2% axons in control vs 87 ⫾ 6% after Neurturin
deprivation). Similar to the effects of NGF withdrawal, Neurturin
deprivation caused caspase 6 activation in axons (Fig. 5B). In
addition, inhibition of caspase 6 as well as overexpression of cytNmnat1 or Bcl-xl blocked axon degeneration induced by Neurturin deprivation (Fig. 5C). These results indicate that caspase 6 is
an important driver of axon degeneration resulting from withdrawal of different classes of neurotrophic factors acting through
unique receptors.

Figure 7. NGF internalization is blocked by Dctn 1 knockdown. A, Fluorescent microscopy of
NGF trafficking using Cy3 labeled NGF. DRG neurons (DIV14) were infected with lentiviruses
expressing either Luciferase (Luc) or Dctn1 siRNA for 7 d. Neurons were deprived of NGF for 16 h
then Cy3 labeled NGF was added to the medium. After 4 h, Cy3 labeled NGF appeared in the cell
bodies of control neurons (Luc siRNA); however, no Cy3 NGF was observed in the neuronal soma
after Dctn1 knockdown (Dctn1 siRNA). B, The percentage of neurons containing Cy3-labeled
NGF in the cell body was determined. Note the normal level of internalized NGF in neurons
expressing Dctn1-3 siRNA that produces poor knockdown and no axonal degeneration. A total
of 400 neurons were analyzed and the experiments were repeated 3 times. Significantly different (*p ⬍ 0.001, Student’s t test) from Luciferase siRNA infected neurons.

8% of control and 54 ⫾ 13% of Nmnat-expressing neuronal cell
bodies remaining refractile and excluding ethidium homodimers
(intact) after 24 h and only 3% at 72 h after NGF withdrawal (Fig.
4 B; supplemental Fig. S4, available at www.jneurosci.org as supplemental material). In contrast, the cell bodies of neurons expressing Bcl-xl were protected from degeneration with 68.7 ⫾
6.8% of cell bodies excluding ethidium homodimer after 72 h of
NGF withdrawal (Fig. 4 B; supplemental Fig. S4, available at
www.jneurosci.org as supplemental material).
We further investigated the mechanism of cell soma protection by examining caspase 3 activation, a marker of apoptotic cell
death. Within 24 h after NGF withdrawal, activated caspase 3 was
detected using cleaved caspase 3-specific antibody in control
neurons, those treated with a caspase 6 inhibitor, and neurons
expressing cytNmnat1. However, no activated caspase 3 was detected in neurons expressing Bcl-xl (Fig. 4C). Bcl-xl protects both
the axon and cell body by inhibiting activation of caspases,
whereas Nmnat mediates only axonal protection via a mechanism that is independent of caspase activation.
To investigate whether the APP/DR6/caspase 6 pathway is
specific for neurotrophins that signal through Trk receptors or is

Axonal degeneration caused by Dctn1 dysfunction can be
inhibited by Nmnat or caspase 6 inhibition
The APP/DR6/caspase 6 signaling pathway plays an important
role in NGF deprivation-mediated axonal degeneration. Mutations that disrupt retrograde axonal transport are often associated with neurological disorders in which axonal degeneration is
an important component. Dctn1 is a component of the dynactin
complex that associates with dynein to drive retrograde axonal
transport of multiple cargoes along the microtubule lattice
(LaMonte et al., 2002; Schroer, 2004). Mutations in DCTN1 are
associated with motor neuron degenerative disorders, ALS associated with frontotemporal dementia (FTD), and Perry syndrome, which has symptoms of Parkinsonism (Puls et al., 2003,
2005; Münch et al., 2004, 2005; Wider and Wszolek, 2008; Farrer
et al., 2009; Vilariño-Güell et al., 2009). These mutations impair
the transport of trophic factor back to the neuronal cell body
(Laird et al., 2008), leading to speculation that neurodegeneration in these patients is due to lack of trophic factors in the soma
(Puls et al., 2005).
Disruption of dynein function leads to decreased NGF transport and increased death in cultured DRG neurons (Wu et al.,
2007). We therefore tested whether depletion of Dctn1 induces
axonal degeneration via activation of the APP/DR6/caspase 6
pathway. DRG neurons were infected with lentiviruses expressing Dctn1 siRNA constructs. We constructed many and extensively used three different Dctn1 siRNAs in these studies. The
efficiency of knockdown for these three siRNAs was quantified
using real-time RT-PCR analysis. We found that Dctn1–1 and
Dctn1-2 siRNAs reduced Dctn1 mRNA levels by 96% and 90%,
respectively; whereas Dctn-3 siRNA resulted in only a 15% reduction in Dctn1 mRNA (supplemental Fig. S6, available at www.
jneurosci.org as supplemental material). DRG neurons were
infected with lentiviruses expressing each of these siRNAs constructs a time when they are critically dependent on NGF (DIV1).
DRG neurons infected with Dctn1-1 or Dctn-2 siRNA showed
extensive axon and soma degeneration, whereas those infected
with Dctn1-3 siRNA were indistinguishable from neurons expressing a Luciferase siRNA (Fig. 6 A–D). Bcl-xl overexpression
blocked both axonal and somal degeneration (Fig. 6 A–D),
whereas cytNmnat1 blocked only axonal degeneration in Dctn1deficient neurons. These results were similar to those obtained
with neurons after NGF withdrawal, suggesting that the mech-
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anism of neuronal damage caused by
Dctn1 knockdown and trophic factor
deprivation is similar.
To assess whether degeneration induced by Dctn1 knockdown is due to
NGF transport deficits, we measured NGF
internalization (see Materials and Methods) and found that depletion of Dctn1
decreases the amount of NGF that is internalized (Fig. 7 A, B). Indeed, the magnitude of the NGF transport defect with
each Dctn siRNA was directly correlated
with the amount of Dctn1 knockdown
and the extent of axon and soma damage.
The axonal degeneration, along with the
NGF trafficking defects, observed in neurons deficient in Dctn1 prompted us to
examine the APP/DR6/caspase 6 pathway
in these neurons. We found that, like NGF
withdrawal, Dctn1 knockdown initiated
loss of surface APP that could be blocked
by BACE inhibition (Fig. 8 A, B). However, in contrast to axon degeneration
after NGF withdrawal, BACE inhibition
or APP-blocking antibody did not block
Dctn1-induced axonal degeneration (Fig.
8C). This is particularly intriguing as caspase
6 inhibition was effective in blocking axonal
degeneration in Dctn1-deficient neurons.
Moreover, Bcl-xl overexpression blocked
both axon degeneration and cell death in
this paradigm (Fig. 6). The surprising dichotomy between blockade of APP surface
loss and caspase 6 inhibition prompted us to
examine caspase 6 activation in neurons expressing Dctn1 siRNA. We found that
caspase 6 was activated in neurons lacking
Dctn1 even in the presence of BACE inhibitors (Fig. 8D), indicating that caspase 6 can
be activated independently of APP cleavage.
Together, these results suggest that deficits
in axonal transport cause axonal degeneration via mechanisms that are similar to
those invoked by trophic factor deprivation
as they both involve caspase 6 activation.
However, since caspase 6 is activated independent of loss of surface APP in Dctndeficient neurons, it appears that multiple
pathways are capable of activating this enzyme and inducing axonal degeneration.

Figure 8. APP-regulated pathways are not involved in axonal degeneration or caspase 6 activation in Dctn1 deficient neurons. A,
Immunofluorescent microscopic analysis using an antibody to the APP N terminus demonstrated the characteristic patchy loss of sAPP on
axons from neurons expressing Dctn1 siRNA. Compare to the continuous staining observed on axons from neurons expressing Luciferase
(Luc)siRNA.TheDctn1siRNA-inducedlossofsAPPwasblockedbytreatmentwithBACEinhibitor(BACEi;OM99-2).B,Quantificationofthe
percentage of axons with decreased sAPP is displayed for each condition (see Materials and Methods). Significantly different from Dctn1
siRNA-expressing neurons (**p ⬍ 0.001). C, Axonal degeneration after Dctn1 knockdown was not blocked by BACE inhibition or anti-NterminalAPP-blockingantibody(abN-APP).SignificantlydifferentfromLuciferasesiRNA-expressingneurons(*p⬍0.001).D,Fluorescent
microscopicanalysisofcaspase6activationinaxonswasperformedusingDRGneuronsinfectedwithlentivirusexpressingeitherLuciferase
(Luc)siRNAorDctn1siRNA.Activationofcaspase6wasdetectedinDctn1siRNA-expressingDRGneurons(Dctn1siRNA)usingcarboxyfluorescein visualization. No caspase 6 activity (fluorescence) was observed in Luciferase siRNA-expressing axons. Dctn1 knockdown induced
strong fluorescence indicating caspase 6 activation. Inhibition of APP cleavage by BACE inhibitor did not block activation of caspase 6 after
Dctn1 knockdown.

Discussion
Axonal degeneration is a hallmark of many debilitating neurological disorders. Identifying the mechanisms that drive such degeneration may lead to treatments that block or delay axon loss. The
recent identification of the APP/DR6/caspase 6 pathway (Nikolaev et al., 2009) was a benchmark in the field because it suggested
rational targets for novel therapeutic interventions. Because this
pathway is well defined, it provided an opportunity to examine
whether it represents a common mechanism, activated in response to multiple insults, to promote axonal degeneration. We
inhibited this pathway at multiple levels: APP cleavage, APP
function, apoptotic pathway activation, or caspase 6 activation;

and discovered that while each of these manipulations block axonal degeneration following trophic factor withdrawal (NGF or
Neurturin), none of them provide axonal protection following
axotomy or vincristine treatment. This implies that multiple
stimulus-dependent pathways can invoke the cascade of events
required to bring about axon demise.
Apoptotic pathways appear to play important roles in axonal
degeneration triggered by trophic factor withdrawal (e.g., NGF or
Neurturin). This is supported by our observation that Bcl-xl
blocks caspase 6 activation and axonal degeneration in neurons
deprived of trophic support. NGF deprivation stimulates parallel
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pathways to induce the apoptotic process and caspase activation.
One is dependent on Bim induction and is responsible for Bax
translocation to mitochondria, whereas the other involves activation of Jnk pathways (Putcha et al., 2001). Moreover, NGF
deprivation activates glycogen synthase kinase 3 (GSK3) at the
axon tip, which initiates an apoptotic signal that travels back to
the neuronal cell body to induce Jun-mediated neuronal apoptosis (Mok et al., 2009). Another GSK3-mediated process that promotes apoptosis is the phosphorylation of Bax and its subsequent
translocation into mitochondria (Linseman et al., 2004). Axonal
retrograde death-promoting signals that lead to apoptotic pathway activation have also been observed in mouse models of ALS
(Perlson et al., 2009). While blocking APP cleavage is clearly
sufficient to suppress axonal degeneration after trophic factor
deprivation, the mechanism of apoptotic pathway activation
downstream of APP cleavage remains to be elucidated.
APP cleavage and activation of apoptotic pathways occurs
after loss of BDNF, NT3, and NGF-mediated Trk receptor
activation (Nikolaev et al., 2009). We found that withdrawal of
Neurturin, which signals through the Ret receptor tyrosine kinase, also stimulated APP/caspase6 axon degeneration signaling
events. The difference between Trk and Ret mediated signaling is
substantial (Klesse and Parada, 1999; Airaksinen and Saarma,
2002; Huang and Reichardt, 2003), yet the loss of signaling after
NGF or Neurturin deprivation appears to stimulate common
axonal degeneration signals. These results suggest that common
adaptor molecules downstream of Trk and Ret receptors (e.g.,
Shc, GRB2, or PI3 kinase) may play key roles in the regulation of
APP processing and axon stability.
The dynein/dynactin1 complex facilitates retrograde axonal
transport of signaling molecules, including neurotrophins, from
the periphery back to the cell body. Mutations in dynactin 1
(DCTN1) are linked to a number of slowly progressing neurological disorders (Puls et al., 2003, 2005; Münch et al., 2004, 2005;
Wider and Wszolek, 2008; Farrer et al., 2009; Vilariño-Güell et
al., 2009), and the neuronal damage in these disorders is speculated to involve loss of trophic factor delivery to the neuronal cell
body. We found that loss of Dctn1 caused impaired NGF trafficking, surface APP loss, and caspase 6 activation. Although caspase
6 inhibition blocked axonal degeneration caused by Dctn1 depletion, inhibition of APP cleavage by inhibiting BACE did not block
the axonal degeneration or caspase 6 activation, suggesting that
caspase 6 activation in Dctn1-depleted neurons is independent of
APP cleavage. This could occur due to impaired retrograde axonal transport in Dctn1-depleted neurons as this would limit the
availability (at the neuronal cell body) of vital factors and signaling molecules associated with signaling endosomes such as
P-Trk, Erk1/2 and Erk5 (Delcroix et al., 2003) to induce apoptotic pathway activation. Furthermore, Dctn1 interacts with Kinesin II to regulate transport of organelles including mitochondria
(Deacon et al., 2003). Dctn1 deficiency could therefore also disrupt neuronal energy homeostasis, another potential mechanism
of caspase 6 activation.
While distinct, stimulus-dependent mechanisms trigger axonal degeneration in response to trophic factor deprivation, mechanical injury, or chemical toxicity; each of these pathways is
blocked by expression of Nmnat1, a component of the Wld s protein (Araki et al., 2004; Sasaki et al., 2006, 2009a,b; Yahata et al.,
2009). Nmnat is the most potent axonal protection factor known,
however, its mechanism of action remains obscure. The requirement for the APP/caspase 6 pathway for axonal degeneration
induced by trophic factor deprivation afforded an opportunity to
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identify where in the cascade Nmnat is exerting its protective
effects. In neurons overexpressing cytNmnat1, NGF withdrawal
still leads to loss of axonal sAPP and activation of axonal caspase
6, yet axonal degeneration does not occur. These findings are
consistent with the prevention of degeneration in caspasepositive dendrites by Wld s protein in Drosophila (Schoenmann et
al., 2010). From these observations, three important aspects of
axonal degeneration emerge: (1) Nmnat influences a step downstream or parallel to caspase 6 activation; (2) caspase 6 activation
does not occur in all axonal injury paradigms; and (3) distinct,
injury-specific pathways of axonal degeneration must converge
on a common, Nmnat-sensitive axonal degeneration program.
Although cytNmnat1 protects axons from degeneration after
loss of trophic support or Dctn1 knockdown, it failed to protect
the cell soma. Our results and previous experiments indicate that
different signaling cascades are responsible for degeneration of
the axon and soma (Nikolaev et al., 2009). For example, after
NGF deprivation inhibitors of caspase 6 and caspase 3 selectively
inhibit axon or soma degeneration, respectively. Further work to
pinpoint the critical substrates of caspase 6 in axons, as well as the
steps in axonal degeneration that are modulated by Nmnat will be
crucial if we are to exploit its potential for treating the axonopathy accompanying neurological disorders.
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Calne S, Calne DB, Lechevalier B, Chapon F, Tsuboi Y, Yamada T, Gutmann
L, Elibol B, Bhatia KP, Wider C, Vilariño-Güell C, Ross OA, Brown LA,
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